Brii Bio completes HK$0.01 million on-market buyback; issued float slips to 721.71 million shares

Bulletin Express10-21

Brii Biosciences Limited (Brii Bio) disclosed that on 21 October 2026 it repurchased 16,000 ordinary shares on the Hong Kong Stock Exchange at HK$0.905 per share, for a total consideration of HK$0.01 million. The shares have been retained as treasury stock.

Following the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.0022 % to 721.71 million shares, while the treasury-share balance rose to 13.61 million. Total issued shares remained unchanged at 735.32 million.

The buyback forms part of the mandate approved on 16 June 2026 that authorises Brii Bio to repurchase up to 72.19 million shares. Cumulative repurchases under this mandate now stand at 0.89 million shares—equivalent to 0.12 % of the company’s issued shares on the mandate date—leaving capacity for a further 71.30 million shares.

In accordance with Hong Kong Listing Rules, Brii Bio is subject to a moratorium on new share issues or sales of treasury shares until 20 November 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment